Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2013 December;55(4) > Panminerva Medica 2013 December;55(4):339-43

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

PANMINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,698


eTOC

 

  PERCUTANEOUS CORONARY AND VASCULAR INTERVENTIONS


Panminerva Medica 2013 December;55(4):339-43

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

The optimal treatment of STEMI: new pharmacological and device approaches

Movahed M. R.

CareMore Health Care Arizona, Division of Cardiology The Southern Arizona VA health Care System Tucson, Arizona and Division of Cardiology University of Arizona, Tucson, AZ, USA


PDF  


Cardiovascular disease remains the leading cause of mortality worldwide. Many deaths are contributed to acute ST elevation myocardial infarction (STEMI). Recently, epidemiological studies have been shown reduction in STEMI related mortality over the last decade. This reduction has partially been attributed to new pharmacological and device advances that were utilized during STEMI treatment. The goal of this manuscript is to review new pharmacological and device approaches available in the treatment of STEMI patients.

top of page

Publication History

Cite this article as

Corresponding author e-mail

rmova@aol.com